John M. Kane III

MD, FACS
Surgical Oncology
Image
2022 Buffalo Spree Top Docs badge

Dr. Kane III is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Specializing In:

Surgical oncology Soft tissue sarcomas at all anatomic locations: extremity, truncal, intra-abdominal/retroperitoneal, head and neck and gastrointestinal stromal tumors (GIST) Melanoma Rare soft tissue and skin tumors Merkel cell carcinoma Cytoreductive/Hyperthermic Intraperitoneal Chemotheraphy (HIPEC) Carcinomatosis, primary peritoneal mesothelioma Isolated regional therapy (Isolated limb perfusion (ILP) and isolated limb infusion (ILI))

About John M. Kane III

Biography:

I am the Chair of Surgical Oncology and Chief of the Melanoma/Sarcoma service at Roswell Park Comprehensive Cancer Center. My interests in melanoma and sarcoma date back to the beginning of my practice in the year 2000. I am the main soft tissue sarcoma surgeon at Roswell Park and treat soft tissue sarcomas at all anatomic locations; extremity, truncal, intra-abdominal/retroperitoneal, head and neck, and gastrointestinal stromal tumors (GIST). I am a member of major sarcoma groups including the National Comprehensive Cancer Network Sarcoma Panel (Vice Chair), the Connective Tissue Oncology Society, and the Society of Surgical Oncology Sarcoma Disease Site Working Group (Vice Chair). I have been the lead investigator for several sarcoma trials at Roswell Park, have authored multiple papers on the treatment of soft tissue sarcomas, and have been an invited speaker on this topic at national meetings. I oversee our weekly sarcoma/soft tissue tumor multidisciplinary conference where all new sarcoma and rare soft tissue tumor cases are discussed in order to develop the optimal treatment plan.

In addition to sarcomas, I treat unusual benign and locally aggressive soft tissue tumors. These include desmoid/aggressive fibromatosis, dermatofibrosarcoma protuberans (DFSP), neurogenic tumors such as neurofibroma and schwannoma, large and atypical intramuscular lipomatous tumors, solitary fibrous tumor, ganglioneuroma, and myelolipoma. As noted above, our weekly multidisciplinary conference allows for a thorough discussion of the patients with these various tumors. In some cases, surgery may not even be necessary.

I also have a significant clinical interest in melanoma and other aggressive cutaneous malignancies such as Merkel cell carcinoma. Roswell Park has been offering melanoma sentinel lymph node biopsy since 1996 and I have personally performed over 600. I have been a co-investigator on the large, international, multi-institutional clinical trials studying melanoma sentinel node biopsy. For patients with nodal metastatic disease, I perform axillary dissections (very different from what is done for breast cancer), superficial and deep groin dissections, and even less common lymphadenectomies in the epitrochlear and popliteal basins. I recently served as the group chair for the “Melanoma” chapter in the American College of Surgeons Operative Standards for Cancer Surgery. I have advanced the regional therapies program at Roswell for patients with isolated extremity disease (in transit melanoma, Merkel cell carcinoma, and some sarcomas) that is no longer amenable to surgical excision. Isolated limb perfusion (ILP) or isolated limb infusion (ILI) can still be potentially curative in these situations. Roswell Park Comprehensive Cancer Center is one of only a few institutions in New York State that performs these isolated regional therapies.

As another type of isolated regional therapy, I developed the cytoreduction/hyperthermic intraperitoneal chemoperfusion (HIPEC) program at Roswell Park Comprehensive Cancer Center in 2002. Roswell Park is also one of only a few centers in New York that offers cytoreductive surgery/HIPEC for appendiceal neoplasms, colorectal cancer, mesothelioma, select ovarian cancer cases, and other peritoneal surface malignancies. Although I no longer perform HIPEC as a regular part of my clinical practice, I continue to play an active role in our HIPEC program.

In addition to my clinical responsibilities, I have previously served as the Surgical Oncology Fellowship Program Director and on the Executive Council of the Society of Surgical Oncology. I am a fellow of the American College of Surgeons and a member of multiple surgical and oncologic societies. I have also served as the past president for both the WNY Chapter of the American College of Surgeons and the Buffalo Surgical Society. I was previously the WNY State Chair for the ACS Commission on Cancer.

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Chair, Surgical Oncology
  • Chief, Melanoma/Sarcoma Service, Department of Surgical Oncology

Background

Education and Training:

  • MD - Johns Hopkins School of Medicine, Baltimore, MD

Residency:

  • Resident - Department of Surgery, University of Pittsburgh, Pittsburgh, PA

Fellowship:

  • Research Fellowship - Department of Surgery, University of Pittsburgh, Pittsburgh, PA
  • Clinical Fellow (SSO approved) - Department of Surgical Oncology - Roswell Park Cancer Institute, Buffalo, NY

Board Certification:

  • American Board of Surgery

Professional Memberships:

  • Society of Surgical Oncology
  • Western New York American College of Surgeons
  • NRG Sarcoma working group
  • Buffalo Surgical Society
  • American College of Surgeons (ACS)
  • ACS - Clinical Research Program Cancer Care Standards Development Committee–Melanoma and Sarcoma Disease Sites

Honors & Awards:

  • Buffalo Spree Top Doctors; 2018-2022
  • 2018 - New York State Troopers PBA, Western Region Chandler Award
  • 2017 - University at Buffalo Jacobs School of Medicine and Biomedical Sciences Gold Humanism Honor Society
  • 2016- Roswell Park Comprehensive Cancer Center Golden Apple Award for the most outstanding Surgical Oncology faculty educator
  • 2010 - University at Buffalo Department of Surgery, Third Year Resident's Best Educational Surgical Rotation
  • 2009 - Roswell Park Golden Apple Award, for the most outstanding Surgical Oncology faculty educator
  • 2006 - University at Buffalo School of Medicine Commendation for Teaching Excellence Award
  • 2005 - Roswell Park Golden Apple Award, for the most outstanding Surgical Oncology faculty educator
  • 2000 - Roswell Park Holyoke Award for the most outstanding Surgical Oncology fellow

Research

Research Overview:

Clinical Trials
  • Principal Investigator: I 255314 “Tissue Procurement Protocol for the Developmental Therapeutics Clinic, NCI”
  • Principal Investigator: I 215912 (NCI-2012-02231, P30CA016056, NCT01744171)  “A Phase I Trial of a Recombinant Human hsp110 gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or Stage IV Melanoma” (closed to accrual).
  • Roswell Park Principal Investigator: PH 47505 “Multicenter Selective Lymphadenectomy Trial II (MSLT II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node (closed to accrual).
Invited International
  • Invited Talk: Standardization of HIPEC –Indications. Fifth International Symposium on Regional Cancer Therapies, Carolina, Puerto Rico, February 20 – 22, 2010
  • Workshop entitled “Establishing a Regional Therapy Program”. Second International Symposium on Regional Cancer Therapies. San Juan, Puerto Rico; February 25, 2007
  • Invited Moderator-Second International Symposium on Regional Cancer Therapies. San Juan, Puerto Rico; February 25, 2007
  • Talk entitled “Current Concepts in Surgical Management of Peritoneal Carcinomatosis: Who & What?” at the Canadian Association of General Surgeons. Montreal, Canada; September 9, 2005
Invited National
  • Invited Talk: Management of Nodal and In-Transit Melanoma, Grand Rounds at Ohio State University, Columbus, OH, November 17, 2011
  • Invited Talk: Management of Nodal and in Transit Melanoma Including Isolated Regional Therapy. Baystate Medical Center. Springfield, MA, April 21, 2011
  • Invited Moderator: 6th International Symposium on Regional Cancer Therapies, Incline Village, Nevada February 19-21, 2011
  • Invited Talk: Multimodality Therapy for Soft Tissue Sarcomas; The Surgeon’s Role in the Management of Gastrointestinal Stromal Tumors (GIST); Treatment of Retro Peritoneal Sarcomas; Management of Nodal and In Transit Melanoma Including Isolated Regional Therapy. 39th Annual Phoenix Surgical Symposium. Scottsdale, AZ; February 10-12, 2011
  • Invited Talk: Challenges in Soft Tissue Sarcoma: Prognostic Factors Including Margins of Resection. American College of Surgeons 96th Annual Clinical Congress, Washington DC; October 7, 2010
  • Invited Talk: Management of Nodal Metastatic and In Transit Melanoma. Third Annual GHS Multidisciplinary Cancer Symposium: Changing Paradigms in Management of Melanoma, Greenville, SC; March 27, 2010
  • Talk entitled “Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Malignancies”. Tripler Army Medical Center Academic Surgery Rounds. Honolulu, HI; May 13, 2009
  • Invited Moderator- Fourth International Symposium on Regional Cancer Therapies, Marco Island, FL; February 23, 2009.
  • Talk entitled “Cytoreduction and HIPEC for Foregut Cancers” Fourth International Symposium on Regional Cancer Therapies, Marco Island, FL; February 23, 2009.
  • Talk entitled “Can Surgery Prevent Cancer” Tripler Army Medical Center Academic Surgery Rounds. Honolulu, HI; May 13, 2008
  • Invited Moderator-Third International Symposium on Regional Cancer Therapies. Palm Desert, CA; February 16, 2008
  • Talk entitled “Advances in the Surgical Treatment of Melanoma” Tripler Army Medical Center Academic Surgery Rounds. Honolulu, HI; March 1, 2006
  • Talk entitled “Management of Carcinomatosis from UGI Malignancies” First International Symposium on Regional Cancer Therapies. Snowmass, CO; January 16, 2006
  • Talk entitled “Advances in the Treatment of Sarcomas” Tripler Army Medical Center Academic Surgery Rounds. Honolulu, HI; September 21, 2005
  • Talk entitled “Overview of Peritoneal Perfusion and Published Results” Innovations in Surgical Oncology Symposium. University of Pittsburgh. Pittsburgh, PA; September 17, 2004
Invited Regional
  • Grand Rounds entitled “Evaluation of Suspicious Soft Tissue Masses”. Catholic Health, Sisters of Charity Hospital, Buffalo, NY, May 22, 2012
  • Talk entitled “Management of Melanoma in Pregnancy” Breast & Gynecologic Cancers: 2009 Update. Roswell Park Cancer Institute, Buffalo, NY, September 26, 2009
  • Talk entitled “Melanoma”. UB Family Medicine Residency lecture. Buffalo, NY; May 1, 2008
  • Grand Rounds entitled “Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Malignancies”. UB Department of Surgery Grand Rounds. Buffalo, NY; April 3, 2008
  • Grand Rounds entitled “Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Malignancies”. Roswell Park Surgical Oncology Grand Rounds. Buffalo, NY; September 12, 2007
  • Talk entitled “Current Surgical Therapy for Melanoma” Advances in Melanoma Symposium. Buffalo, NY; June 17, 2006
  • Talk entitled “Regional Multimodality Therapy for Carcinomatosis” Wisconsin Surgical Club-UB meeting. Buffalo, NY; May 2006
  • Talk entitled “Advances in the Treatment of GIST” Cayuga Medical Center Tumor Board. Ithaca, NY; July 13, 2005
  • Grand Rounds entitled “Advances in the Treatment of GIST” University at Buffalo Community Surgeons. Buffalo, NY; January 29, 2005
  • Talk entitled “Staging and Surgical Therapy for Primary and Recurrent GIST”. Optimal Management of Patients with GIST-NCCN Update-Roswell Park Cancer Institute, Buffalo, NY; November 6, 2004
  • Grand Rounds entitled “Advances in the Treatment of Sarcomas” WCA Hospital. Jamestown, NY; September 29, 2004
  • Grand Rounds entitled “Advances in the Treatment of Carcinomatosis” Millard Gates Hospital. Buffalo, NY; April 5, 2004
  • Grand Rounds entitled “Advances in the Treatment of Sarcomas” Olean General Hospital. Olean, NY; August 13, 2003
  • Grand Rounds entitled “Advances in the Treatment of Carcinomatosis” Mercy Hospital. Buffalo, NY; February 12, 2003
  • Grand Rounds entitled “Advances in the Treatment of Sarcomas” Millard Gates Hospital. Buffalo, NY; January 6, 2003
  • Grand Rounds entitled “Advances in the Treatment of Melanoma” WCA Hospital. Jamestown, NY; October 30, 2002
  • Grand Rounds entitled “Advances in the Treatment of Melanoma” Niagara Falls Memorial Medical Center. Niagara Falls, NY; October 9, 2002

Featured on Cancer Talk


Publications

Full Publications list on PubMed

Salerno K, Alektiar A, Baldini E, Bedi M, Bishop A, Bradenfield L, Chung P, DeLaney T, Folpe A, Kane JM 3rd, Li X, Petersen I, Powell J, Stolten M, Thorpe S, Trent J, Voermans M, Guadagnolo A. Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline. 2021 July. Practical Radiation Oncology.

von Mehren M, Kane JM 3rd, Bui MM, Choy E, Connelly M, Dry S, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Meyer C, Pappo AS, Parkes AM, Paz IB, Petersen IA, Poppe M, Riedel RF, Rubin B, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Bergman MA, George GV. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. 2020, December 2. PMID: 32285515

Kane JM 3rd, Magliocco A, Zhang Q, Wang D, Klimawicz A, Harris J, Simko J, DeLaney T, Kraybill W, Kirsch DG. Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation. Sarcoma. 2018 Feb 28;2018:8310950. PMID: 29681762

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM 3rd, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or
Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 Jun 8;376(23):2211- 2222. PMID: 28591523 PMCID: PMC5548388

Trans-Atlantic RPS Working Group. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2016 Oct;23(11):3531-40. doi:10.1245/s10434-016-5336-7. PubMed PMID: 27480354.